andecaliximab   

GtoPdb Ligand ID: 9510

Synonyms: GS-5745 | GS5745
Compound class: Antibody
Comment: Gilead Sciences designed andecaliximab (GS-5745), a humanized anti-MMP9 monoclonal antibody, for potential to treat solid tumours and inflammatory disorders [1-2]. GS-5745 inhibits MMP-9 activity by a combination of blocking proenzyme (zymogen) conversion to active enzyme, and allosterically inhibiting active MMP-9 catalytic activity [1].
No information available.
Summary of Clinical Use
Andecaliximab (GS-5745) is being evaluated in various clinical trials (max Phase 3) for cancers and inflammatory conditions. Click here to link to all of the trials registered with ClinicalTrials.gov. Trials in ulcerative colitis and Crohn's disease were terminated early (2016) due to meeting pre-specified futility and efficacy criteria in an interim analysis of unblinded efficacy and safety data. A Phase 2 study in rheumatoid arthritis has also been terminated. Evaluation for anti-cancer efficacy appears to be ongoing. Phase 2 trial NCT02864381 is evaluating andecaliximab in combination with the anti-PD-1 checkpoint inhibitor nivolumab in unresectable or recurrent gastric or gastroesophageal junction adenocarcinoma.
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT02864381 Andecaliximab Combined With Nivolumab Versus Nivolumab Alone in Adults With Unresectable or Recurrent Gastric or Gastroesophageal Junction Adenocarcinoma Phase 2 Interventional Gilead Sciences